Drugs / FLU-QIV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04841577 | Apr → Sep 2021 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLU-QIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04841577 ↗ |
| Modality | Vaccine | “seasonal quadrivalent influenza vaccine (FLU-QIV)” NCT04841577 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT04841577 ↗ |